NCT04219579

Antithrombin III Concentrate After Liver Transplantation

Continuous Versus Intermittent Infusion of Human Antithrombin III Concentrate in the Immediate Postoperative Period After Liver Transplantation

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 130 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to demonstrate more effective administration method of AT-III in immediate post-liver transplantation period.

Detailed description

Antithrombin III(AT-III) concentrates have been used to prevent critical thrombosis in the immediate post-liver transplantation period without clear evidence regarding the optimal dose or administration scheme. The investigators retrospectively analyzed the clinical data from the patients who received liver transplantation and developed pharmacokinetic model of AT-III in the previous research. According to this study, optimal AT-III activity level will be well-maintained with smaller dose with continuous infusion than with intermittent infusion which is widely accepted way of administration currently. A prospective study was planned to show the more effective manner of AT-III concentrate administration after liver transplantation.

Conditions

• Liver Transplant; Complications

Interventions

Type	Name	Description
DRUG	Antithrombin III, continuous infusion	Antithrombin-III is administered continuously
DRUG	Antithrombin III, Intermittent infusion	Antithrombin-III is administered intermittently

Timeline

• Start date: 2020-01-03
• Primary completion: 2022-06-28
• Completion: 2022-06-30
• First posted: 2020-01-07
• Last updated: 2022-07-01

Locations

1 site across 1 country: South Korea